In order to facilitate optimal detection and assessment of liver fibrosis and steatosis, the newly launched Hepatus 6 Diagnostic Ultrasound System offers the capabilities of real-time two-dimensional ultrasound with visual transient elastography in one device.
Offering a variety of automated tools and enhanced diagnostic functionality to aid in the diagnosis and quantification of liver fibrosis and steatosis, Minday has launched the Hepatus 6 Diagnostic Ultrasound System.
In addition to the benefits of two-dimensional (2D) and color Doppler imaging for the assessment of liver morphology, Mindray said the Hepatus 6 Diagnostic Ultrasound System provides access to visual transient elastography (ViTE) in the same device.
Automated features include quantitative analysis of liver stiffness, liver ultrasound attenuation analysis and one-click capture of 10 automated Q-scan measurements of fibrosis and steatosis within seconds, according to Mindray.
“The Hepatus 6 system provides clinicians a clear view of patient liver health and helps create a clear path forward for patients with chronic liver disease like no other system on the market today,” noted Wayne Quinn, the president of Mindray North America.
Mindray said another aspect of the Hepatus 6 Diagnostic Ultrasound System includes the ability to switch between the ViTE transducer and the curved ultrasound transducer to see greater real-time detail. The company added that an adjustable panel facilitates ergonomic workflow.
(Editor’s note: For related content, see “MRI Study Shows Higher Fibrosis Risk Among First-Degree Relatives of People with NAFLD and Advanced Fibrosis” and “Can Deep Learning Enhance Ultrasound Assessment of Hepatic Steatosis in Patients with NAFLD?”)
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.